Since IL-13 uses the type II IL-4 receptor, which is comprised of IL-4Rα (CD124) and IL-13Rα (CD213a), the efficacy of Dupliumab supports the notion that IL-13 may be the more important cytokine in terms of asthma pathology. The gene discussed is IL13; the disease is asthma.